Group 1 - The core viewpoint of the article is that Xiansheng Zaiming Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC as joint sponsors [1] - The company, established in 2020, focuses on the research, development, and commercialization of innovative oncology drugs, having five commercialized innovative drugs and over 15 high-potential candidates in clinical and IND application preparation stages [1] - According to a report by Aoyishi Consulting, by 2025, the company is expected to complete three out-licensing transactions, ranking first in the number of oncology asset transactions and fourth in total transaction value among Chinese biopharmaceutical companies [1]

Company Overview - Xiansheng Zaiming Pharmaceutical Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange on January 9, with Morgan Stanley and CICC as joint sponsors [1] - The company was established in 2020, focusing on the research, development, and commercialization of innovative cancer drugs [1] - It has five commercialized innovative drugs and over 15 high-potential candidates in clinical and IND application preparation stages, along with multiple discovery projects [1] Market Position - According to a report by Aoyishi Consulting, by 2025, the company is expected to complete three out-licensing transactions, ranking first in the number of oncology asset transactions and fourth in total transaction value among Chinese biopharmaceutical companies [1]

先声再明为一家处于全球药物创新前沿的生物制药企业，聚焦于肿瘤创新药物的研究、开发与商业化 (不包括与细胞疗法及基因诊断与治疗技术相关的药物)。 待建议分拆及建议上市完成后，本公司预期将拥有先声再明超过50%的权益，而先声再明将仍然为本公 司的附属公司。 智通财经APP讯，先声药业(02096)发布公告，本公司建议分拆本公司附属公司先声再明的H股在联交所 主板独立上市。先声再明H股于联交所主板独立上市构成本公司根据第15项应用指引分拆先声再明。联 交所已确认本公司可进行建议分拆。 于2026年1月9日，先声再明就申请先声再明H股于联交所主板上市及获准买卖，向联交所递交上市申请 表格(A1表格)。按照计划，先声再明将就建议上市进行新股发售。受限于若干条件，合资格股东将可透 过在全球发售项下优先申请先声再明H股的方式，而获提供先声再明H股的保证配额。 ...